Let's see if we can logically build on it. You say the US potential is 150 devices; But here's what they just said about 2012: "Record lithotripsy sales with 21 devices sold in fourth quarter and 52 devices sold during full year."
They thus sold 31 devices during the first 9 months of 2012 and lost money doing it. If the total US potential is 150, say spread over 3 years (i.e, 50 per year), the potential to make any sizeable profit seems limited. We should expect that they made a BIG profit from the 21 sold in the last quarter. But what would that be? Two million? Five million? Too bad they can't tell us a little sooner than next month. I would hope they are trying hard to wrap up the books for 2012 so they can get that info (which we all would expect to be very positive) out as soon as they can. Top priority. What do they sell an individual device for? How much of their revenue will be from on-going maintenance?
High-intensity Focused Ultrasound for Prostate Cancer
High-intensity focused ultrasound (HIFU) is a minimally invasive technology that destroys cancerous prostate tissue.
According to manufacturer information, three private clinics in Canada offer HIFU for prostate cancer treatment.
How it Works
While patients receive spinal or general anesthesia, a probe emits a precise beam of HIFU through the rectal wall to the prostate gland, creating a sudden temperature rise that destroys the targeted tissue. Real-time monitoring is done by ultrasound or magnetic resonance imaging (MRI). The HIFU procedure takes one to three hours and patients require urinary catheterization for seven to 14 days post-operatively.
HIFU is an alternative treatment to radical prostatectomy (surgical removal of part or all of the prostate) and radiation in men with well, or moderately differentiated, tumours and a life expectancy of more than five years. Advantages include low complication rates, and the ability to repeat treatment or use additional interventions in the future. Used for either primary or salvage (recurrence) therapy, HIFU may be an option for those ineligible for prostatectomy.
Prostate Cancer in Canada
In 2006, about 20,700 Canadian men will be diagnosed with prostate cancer, and 4,200 will die from the disease.
Health Canada has licensed two HIFU systems: Ablatherm® (EDAP TMS S.A.,Vaulx-en-Velin, France)in April 2003, and Sonablate® 500 (Focus Surgery Inc., Indianapolis, IN) in June 2005.
Three small, non-randomized, uncontrolled trials report five years’ of experience with HIFU.[3-5] In the first trial, at 22 months of follow-up, 87% of 137 patients had low levels (